LON:ABZA - Abzena Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 15.75
+0.30 (1.20%)

This chart shows the closing price for ABZA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abzena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABZA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABZA

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Abzena in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 15.75.

This chart shows the closing price for ABZA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Abzena. This rating has held steady since July 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/1/2018Peel HuntReiterated RatingBuy
7/2/2018Liberum CapitalReiterated RatingBuyGBX 40
7/2/2018Peel HuntReiterated RatingBuyGBX 40
6/14/2018Peel HuntReiterated RatingBuy
6/4/2018Numis SecuritiesReiterated RatingBuy
5/31/2018Peel HuntReiterated RatingBuyGBX 42 ➝ GBX 40
4/16/2018Numis SecuritiesReiterated RatingBuyGBX 80 ➝ GBX 62
4/16/2018Peel HuntReiterated RatingBuyGBX 42
4/10/2018Peel HuntReiterated RatingBuyGBX 42
4/4/2018Peel HuntReiterated RatingBuy
3/27/2018Peel HuntReiterated RatingBuyGBX 42
3/5/2018Peel HuntReiterated RatingBuyGBX 42
2/8/2018Peel HuntInitiated CoverageBuyGBX 42
12/13/2017Numis SecuritiesReiterated RatingBuyGBX 80
12/11/2017FinnCapReiterated RatingBuyGBX 70
11/21/2017FinnCapReiterated RatingBuyGBX 70
9/22/2017FinnCapLower Price TargetBuyGBX 80 ➝ GBX 70
9/14/2017Numis SecuritiesReiterated RatingBuyGBX 80
9/14/2017FinnCapReiterated RatingUnder Review
8/30/2017FinnCapReiterated RatingBuyGBX 80
8/24/2017FinnCapReiterated RatingBuyGBX 80
7/11/2017Numis SecuritiesReiterated RatingBuyGBX 93
6/14/2017FinnCapReiterated RatingBuyGBX 80
5/30/2017FinnCapReiterated RatingBuyGBX 80
5/26/2017Numis SecuritiesReiterated RatingBuyGBX 93
5/24/2017FinnCapReiterated RatingBuyGBX 80
4/28/2017FinnCapReiterated RatingBuyGBX 100 ➝ GBX 80
4/26/2017N+1 SingerReiterated RatingCorporate
4/6/2017N+1 SingerReiterated Ratingcorporate
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 90
3/6/2017N+1 SingerReiterated RatingCorporate
3/2/2017FinnCapReiterated RatingBuyGBX 100
2/24/2017FinnCapReiterated RatingBuyGBX 100
2/21/2017Numis SecuritiesReiterated RatingBuyGBX 90
2/21/2017N+1 SingerReiterated RatingCorporate
1/20/2017N+1 SingerReiterated RatingCorporate
1/20/2017Numis SecuritiesReiterated RatingBuyGBX 90
12/22/2016N+1 SingerReiterated RatingCorporate
12/2/2016Numis SecuritiesInitiated CoverageBuyGBX 90
11/30/2016N+1 SingerReiterated RatingCorporate
11/29/2016FinnCapReiterated RatingBuyGBX 100
11/24/2016N+1 SingerReiterated RatingCorporate
11/18/2016FinnCapReiterated RatingBuy
11/10/2016FinnCapInitiated CoverageBuyGBX 100
10/21/2016N+1 SingerReiterated RatingCorporate
(Data available from 6/24/2016 forward)
Abzena logo
Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: GBX 15.75
Low: 15.75
High: 15.75

50 Day Range

MA: GBX 15.75
Low: 15.75
High: 15.75

52 Week Range

Now: GBX 15.75
Low: 6
High: 33.70

Volume

100 shs

Average Volume

220,500 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abzena?

The following Wall Street research analysts have issued reports on Abzena in the last twelve months:
View the latest analyst ratings for ABZA.

What is the current price target for Abzena?

0 Wall Street analysts have set twelve-month price targets for Abzena in the last year. has the lowest price target set, forecasting a price of £100,000 for Abzena in the next year.
View the latest price targets for ABZA.

What is the current consensus analyst rating for Abzena?

Abzena currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ABZA.

What other companies compete with Abzena?

How do I contact Abzena's investor relations team?

Abzena's physical mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company's listed phone number is +44-1223-903498. The official website for Abzena is www.abzena.com.